INBRX-109 led to a disease control rate of 87.1% – Vivek Subbiah
We always need new & better to potentially best-in-class drugs with novel mechanisms of action. Just published in American Association for Cancer Research journal Clinical Cancer Research simultaneously with the American Society of Clinical Oncology (ASCO) 2023 meeting.
Presenting a new- DR5 drug for patients with chondrosarcoma
–>Started working with a 1st gen DR5 targeting treatment in 2012
FINALLY we have a 3rd generation DR5 drug with activity in chondrosarcoma!!!
INBRX-109 led to a disease control rate of 87.1% (27/31), including 2 partial responses + median PFS of 7.6 months.
Thankful to all patients, caregivers & all co-investigators, the clinical trial staff who worked behind the scenes in the pandemic to keep this trial going & last but not least Inhibrx, Inc. team for supporting us doing a clinical trial in #chondrosarcoma a rare disease.
Source: Vivek Subbiah / LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023